The stock of Amarin Corporation Plc Ads (NASDAQ:AMRN) registered a decrease of 25.67% in short interest. AMRN’s total short interest was 14.17M shares in September as published by FINRA. Its down 25.67% from 19.06 million shares, reported previously. With 3.39M shares average volume, it will take short sellers 4 days to cover their AMRN’s short positions. The short interest to Amarin Corporation Plc Ads’s float is 7.76%. The stock decreased 3.73% or $0.11 during the last trading session, hitting $2.84. About 3.35M shares traded hands. Amarin Corporation plc (ADR) (NASDAQ:AMRN) has risen 126.92% since February 8, 2016 and is uptrending. It has outperformed by 110.43% the S&P500.
Amarin Corporation plc is a biopharmaceutical firm with activities in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The company has a market cap of $551.88 million. The Company’s lead product, Vascepa capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It currently has negative earnings. The Firm operates in the business segment of development and commercialization of Vascepa.
The institutional sentiment increased to 1.04 in 2016 Q2. Its up 0.41, from 0.63 in 2016Q1. The ratio increased, as 9 funds sold all Amarin Corporation plc (ADR) shares owned while 17 reduced positions. 7 funds bought stakes while 20 increased positions. They now own 30.07 million shares or 19.93% less from 37.56 million shares in 2016Q1.
Opaleye Management Inc. holds 6.17% of its portfolio in Amarin Corporation plc (ADR) for 1.25 million shares. Oracle Investment Management Inc owns 5.69 million shares or 2.86% of their US portfolio. Moreover, Pura Vida Investments Llc has 1% invested in the company for 1.09 million shares. The New York-based Broadfin Capital Llc has invested 0.98% in the stock. Greenwich Wealth Management Llc, a Connecticut-based fund reported 15,000 shares.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.